# Estimating the Population Benefits of Blood Pressure Lowering: A Wide-Angled Mendelian Randomization Study in UK Biobank

Hannah Higgins MPhil<sup>1</sup>, Amy M. Mason PhD<sup>1</sup>, Susanna C. Larsson PhD<sup>2,3</sup>, Dipender Gill BMBCh PhD<sup>4-8</sup>, Claudia Langenberg MD PhD<sup>9</sup>, Stephen Burgess PhD<sup>1,10</sup>

- 1. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
- 2. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- 3. Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- 4. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
- 5. Centre for Pharmacology and Therapeutics, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK.
- Department of Genetics, Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK.
- Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, UK.
- 8. Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK.
- 9. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
- 10. Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK.

Correspondence to: Stephen Burgess. Email: <u>sb452@medschl.cam.ac.uk</u>.

Short title: Population benefits of lower blood pressure

Journal Subject Terms: Cardiovascular disease, high blood pressure, epidemiology, risk factors,

hypertension

## 1 Abstract

2	Background: The causal relevance of elevated blood pressure for several cardiovascular					
3	diseases is uncertain, as is the population impact of blood pressure lowering on risk of					
4	cardiovascular diseases more broadly. This study systematically assesses evidence of					
5	causality for various cardiovascular diseases in a two-sample Mendelian randomization					
6	framework, and estimates the potential reduction in the prevalence of these diseases					
7	attributable to long-term population shifts in the distribution of systolic blood pressure (SBP).					
8	Methods and Results: We investigated associations of genetically-predicted SBP as					
9	predicted by 256 genetic variants with 21 cardiovascular diseases in UK Biobank, a					
10	population-based cohort of UK residents. The sample consisted of 376,703 participants of					
11	European ancestry aged 40-69 years at baseline. Genetically-predicted SBP was positively					
12	associated with 14 of the outcomes (p<0.002), including dilated cardiomyopathy,					
13	endocarditis, peripheral vascular disease, and rheumatic heart disease. Using genetic variation					
14	to estimate the long-term impact of blood pressure lowering on disease, population reductions					
15	in SBP were predicted to result in an overall 16.9% (95% confidence interval (CI): 12.2-					
16	21.3%) decrease in morbidity for a 5 mmHg decrease from a population mean of 137.7					
17	mmHg, 30.8% (95% CI: 22.8-38.0%) for a 10 mmHg decrease, and 56.2% (95% CI: 43.7-					
18	65.9%) decrease for a 22.7 mmHg decrease in SBP (22.7 mmHg represents a shift from the					
19	current mean SBP to 115 mmHg).					
20	Conclusions: Risk of many cardiovascular diseases is influenced by long-term differences in					
21	SBP. The burden of a broad range of CVDs could be substantially reduced by long-term					
22	population-wide reductions in the distribution of blood pressure.					
23						
24	Key Words: Cardiovascular disease, Mendelian randomization, high blood pressure,					

25 hypertension, genetic epidemiology.

## 1 Introduction

2	High blood pressure has severe, costly consequences largely through increased cardiovascular					
3	disease (CVD) risk <sup>1</sup> . For many CVDs, a causal relationship with blood pressure that is					
4	reversible through treatment has been demonstrated in randomized controlled trials (RCTs) <sup>2</sup> .					
5	However, for diseases such as dilated cardiomyopathy, endocarditis, peripheral vascular					
6	disease, and aortic valve stenosis, RCT evidence demonstrating a causal effect of blood					
7	pressure lowering is lacking. Despite this, these outcomes have been used to estimate the					
8	population impact of raised blood pressure <sup>3</sup> . Additionally, quantitative evidence for the					
9	benefit of reducing blood pressure has not been assessed for several CVD outcomes in a					
10	primary prevention setting.					
11						
12	In the absence of RCT evidence, Mendelian randomization (MR) can circumvent several					
13	limitations of observational epidemiology, allowing unconfounded inferences from					
14	observational data <sup>4</sup> . MR uses selected genetic variants related to an exposure to provide					
15	evidence supporting a causal hypothesis. The independent segregation of alleles at conception					
16	means that genetically-defined subgroups of the population with increased or decreased					
17	average blood pressure levels should not differ systematically with respect to confounding					
18	variables, creating a natural experiment analogous to an RCT <sup>4</sup> . Life-long average differences					
19	in the exposure between subgroups compared in an MR analysis provide evidence regarding					
20	the potential impact of long-term interventions on the exposure, in contrast to the short-term					
21	interventions usually evaluated by RCTs <sup>5</sup> .					
22						
23	Here, we employ MR to assess evidence for causality between systolic blood pressure (SBP)					
24	and a broad range of CVDs in UK Biobank, a population-based cohort of UK residents. We					

25 then use these estimates to predict the potential reduction in cardiovascular disease burden in

- 1 the UK population attributable to distributional shifts in SBP. We focus on SBP as a measure
- 2 of blood pressure because it is a better predictor of health outcomes than diastolic blood
- 3 pressure (DBP)<sup>1</sup>. However, as the genetic variants used in this investigation are associated
- 4 with both SBP and DBP, estimates relate generally to blood pressure lowering and are not
- 5 specific to SBP.
- 6

## 1 Methods

2	We performed two-sample Mendelian randomization analyses using summarized data
3	(eFigure 1). Genetic associations with blood pressure were obtained in 299,024 European
4	ancestry participants from the International Consortium for Blood Pressure (ICBP) <sup>6</sup> . Genetic
5	associations with 21 CVDs were estimated in 376,703 European ancestry participants from
6	UK Biobank <sup>7</sup> by logistic regression with adjustment for age, sex, and 10 genomic principal
7	components (eTable 1). As the ICBP and UK Biobank samples do not overlap, bias due to
8	winner's curse is avoided. As genetic instruments, we selected 256 variants previously
9	associated with blood pressure at a genome-wide level of significance in the ICBP dataset
10	(eTable 2). The variants explained 2.1% of variance in SBP in ICBP, corresponding to an F-
11	statistic of 23.1. Associations between a weighted genetic risk score (GRS) and potential
12	confounders (sex, age, BMI, smoking status, low-density lipoprotein [LDL] cholesterol,
13	alcohol drinker status, and anti-hypertensive medication status) were assessed in UK Biobank.
14	
15	Mendelian randomization estimates for the casual effect of SBP on the odds of 21 CVD
16	outcomes were obtained using the inverse-variance weighted (IVW) method <sup>8</sup> . Estimates are
17	odds ratios per 10 mmHg increase in genetically-predicted SBP. Sensitivity analyses were
18	performed using the MR-Egger, weighted median, and MR-PRESSO methods <sup>8</sup> . Outcomes
19	with strong evidence for causality (p-value $< 0.05/21 = 0.002$ in either IVW or MR-PRESSO
20	method and concordance of estimates across all methods) were used to estimate the change in
21	disease burden that would occur under interventions in the distribution of SBP. Assuming a
22	linear model, we estimated the population impact fraction <sup>3</sup> , representing the relative
23	reduction in disease risk if mean SBP were set to a given value for all individuals in the
24	population. We also estimated the absolute reduction in events from a population shift in the

- 1 distribution of SBP using disease prevalence estimates from surveys relevant to a middle- to
- 2 early late-aged UK-based population (eTable 3).

#### 1 **Results**

2 SBP was approximately normally distributed with a mean of 137.7 mmHg (standard 3 deviation 18.6 mmHg) (eFigure 2). There was no association between the GRS and age, sex, 4 smoking, or alcohol consumption (Table 1). The GRS was associated with BMI and with 5 LDL cholesterol (mean difference between top versus bottom 50%: 4.1 mmHg for SBP, -0.1 kg/m<sup>2</sup> for BMI, -0.04 mmol/L for LDL-cholesterol). Hence any influence of BMI or LDL-6 7 cholesterol on estimates via pleiotropy should be minimal, and would generally result in 8 underestimation of the effect of SBP as both BMI and LDL-cholesterol increase the risk of 9 most CVDs.

10

11 Fourteen outcomes satisfied the criteria of strong evidence for causality: p < 0.002 and 12 concordance of estimates across methods (Figure 1, eTable 4). In decreasing order of the 13 IVW estimate, these were: aortic valve stenosis, ischemic stroke, dilated cardiomyopathy, 14 coronary artery disease, subarachnoid hemorrhage, ischemic cerebrovascular disease, 15 endocarditis, hemorrhagic stroke (all), chronic kidney disease, heart failure, transient 16 ischemic attack, atrial fibrillation, rheumatic heart disease, and peripheral vascular disease 17 (eFigure 3). Two further outcomes (intracerebral hemorrhage and aortic aneurysm) had a 18 positive IVW estimate at a conventional level of statistical significance (p<0.05). Deep vein 19 thrombosis had an inverse IVW estimate at a conventional level of statistical significance 20 (p<0.05).

21

Figure 2 shows the estimated changes in the absolute prevalence of outcomes with strong evidence for causality resulting from a population shift in the distribution of SBP. Population impact fractions for these outcomes are provided in eTable 5. Aggregating across these outcomes, reductions in SBP were predicted to result in an overall 16.9% (95% confidence

- 1 interval (CI): 12.2-21.3%) decrease in CVD morbidity for a 5 mmHg SBP decrease from a
- 2 population mean of 137.7 mmHg, 30.8% (95% CI: 22.8-38.0%) for a 10 mmHg SBP
- decrease, and 56.2% (95% CI: 43.7-65.9%) decrease for a 22.7 mmHg SBP decrease 22.7
- 4 mmHg represents a shift from the current mean SBP in the population to 115 mmHg, a value
- 5 that has been proposed as a theoretical minimum risk target.
- 6

#### 1 **Discussion**

While for many CVDs the causal effect of blood pressure lowering has been demonstrated convincingly in RCTs, several outcomes (dilated cardiomyopathy, endocarditis, peripheral vascular disease, and rheumatic heart disease) had previously only been shown to be associated with SBP in observational studies <sup>1,3</sup>. Our analysis adds evidential weight to blood pressure as a causal risk factor for these outcomes and to their inclusion in other SBP population impact studies.

8

9 Although the majority of the outcomes associated with genetically-predicted SBP are chronic 10 diseases, some have infectious origins (for example, endocarditis and rheumatic heart 11 disease). Elevated SBP may therefore increase susceptibility to, or damage from, infection. A 12 notable finding was the inverse association between genetically-predicted SBP and deep vein 13 thrombosis. Although this association did not achieve statistical significance after accounting 14 for multiple testing, an inverse association between SBP and venous thromboembolism has 15 been found in previous observational studies <sup>9,10</sup>.

16

The MR estimates obtained here were generally larger than those from RCTs. For example, the MR estimate for the risk of ischemic stroke per 10 mmHg increase in SBP was 1.70 (95% CI: 1.52-1.90). This contrasts with an estimate of 1.27 (95% CI: 1.23-1.32) from a recent meta-analysis of RCTs<sup>2</sup>. While this is expected as MR estimates represent the lifelong impact of elevated blood pressure whereas RCTs vary blood pressure for a shorter period <sup>11</sup>, other factors such as trial setting and inclusion criteria may also contribute.

23

24 This study has many strengths, but also limitations. The large sample size and wide range of 25 outcomes enables systematic cross-comparisons of unconfounded estimates in a single

cohort. This is important from a public health perspective when comparing the impact of the
 same genetic change on different diseases. The genome-wide genotypic data available from
 the cohort absolved any need to use proxy SNPs in the instrument. However, the results
 should be interpreted in the context of several limitations.

5

6 First, the UK Biobank cohort is somewhat unrepresentative of the UK population and suffers from 'healthy volunteer' selection bias <sup>12</sup>. Analyses were conducted in participants of 7 8 European descent to avoid population stratification. A recent GWAS identified only modest 9 correlation of blood pressure effect estimates across ancestries <sup>13</sup>. Estimates may therefore 10 not be fully relevant for the whole UK population. Whether the findings are applicable to 11 other ethnicities warrants investigation, particularly since hypertension disproportionately affects black African and Caribbean ancestry ethnic groups both in the UK and abroad <sup>14</sup>. 12 Given large global disparities in hypertension prevalence (both by country and ancestry <sup>15</sup>), 13 14 generalizability beyond the UK of the public health modelling may be limited.

15

The MR approach is underpinned by assumptions that cannot be completely empirically validated <sup>4</sup>. However, the GRS for SBP was not strongly associated with major confounders and estimates were generally similar across robust methods. Furthermore, the relevance ssumption was fulfilled: all SNPs were significantly associated with SBP and the entire genetic instrument explained 2.1% of variance in SBP in the ICBP GWAS, corresponding to an F-statistic of 23.1.

22

Although the principles of MR seek to emulate an RCT, the approach differs fundamentally in certain aspects which are relevant when using MR in public health modelling. Firstly, the results presented here reflect lifelong differences in SBP relating to genetic variants that are

determined at conception. The reversibility of these long-term effects is unknown, however,
reversibility is assumed in the population impact fraction calculations. Whilst the SBPassociated risks of most cardiovascular outcomes have demonstrated reversibility from RCTs,
it is unknown whether this applies to the full spectrum of outcomes studied here. There may
be no existing intervention applicable to a mature cohort which can imitate the genetic effect,
and if such an intervention does exist, the time-lag or age target required to produce the
predicted effects is unknown <sup>4</sup>.

8

9 Finally, these analyses assume linearity of effects <sup>1</sup>. Estimates are likely to be reliable for
10 shifts in SBP of similar magnitude to the genetic associations with SBP, which are around 810 mmHg. However, the appropriateness of extrapolation to larger changes in SBP cannot be
12 assessed in this current study.

13

14 The evidence presented here suggests that incidence of diseases later in life is influenced by 15 long-term, lifelong differences in SBP exposure, even in lower-risk populations. Therefore, confining interventions to older age groups and individuals over a certain risk threshold will 16 17 only partially address the totality of disease burden. Interventions that may replicate the 18 lifelong reduction in exposure to elevated SBP evaluated here include non-pharmalogic 19 interventions, such as physical activity, weight control, and sodium reductions, and 20 community-wide programmes, such as consumer awareness campaigns and industry 21 collaboration for food reformulation.

22

In conclusion, reducing systolic blood pressure by 10 mmHg could reduce the overall burden
of a broad range of CVDs by around 30%. These findings contribute to an ever-expanding

- 1 body of evidence advocating targeted and population-based strategies for management of
- 2 high blood pressure across the life course.

#### **1** Sources of Funding

- 2 Dr Mason is funded by the National Institute for Health Research (Cambridge Biomedical
- 3 Research Centre at the Cambridge University Hospitals NHS Foundation Trust) and by a
- 4 European Council Innovative Medicines Initiative (BigData@Heart). Dr Larsson has
- 5 received grants from the Swedish Research Council for Health, Working Life and Welfare
- 6 (Forte; grant no. 2018-00123), the Swedish Research Council (Vetenskapsrådet; Grant
- 7 number 2019-00977), and the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant no.
- 8 20190247). Dr Burgess is supported by Sir Henry Dale Fellowship jointly funded by the
- 9 Wellcome Trust and the Royal Society (204623/Z/16/Z). Dr Gill is supported by the
- 10 Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of
- 11 Research Excellence (RE/18/4/34215) at Imperial College London. Dr Langenberg is funded
- 12 by the Medical Research Council.

#### 13 Acknowledgements

14 This research was conducted using the UK Biobank study under Application Number 29202.

#### 15 **Conflict of Interest Disclosures**

- 16 Dr Gill is employed part-time by Novo Nordisk outside the submitted work. Hannah Higgins
- 17 is employed full-time by Public Health England outside the submitted work.

## 1 **References**

2	1.	Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic
3		Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2019;98121(2):165-
4		182. doi:10.1001/jama.2016.19043
5	2.	Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of
6		cardiovascular disease and death: a systematic review and meta-analysis. Lancet
7		(London, England). 2016;387(10022):957-967. doi:10.1016/S0140-6736(15)01225-8
8	3.	Collaborators G 2017 RF. Global, regional, and national comparative risk assessment
9		of 84 behavioural, environmental and occupational, and metabolic risks or clusters of
10		risks for 195 countries and territories, 1990 – 2017: a systematic analysis for the
11		Global Burden of Disease S. 2019:1990-2017. doi:10.1016/S0140-6736(18)32225-6
12	4.	Burgess S, Scott RA, Timpson NJ, et al. Using published data in Mendelian
13		randomization: A blueprint for efficient identification of causal risk factors. Eur J
14		Epidemiol. 2015;30(7):543-552. doi:10.1007/s10654-015-0011-z
15	5.	Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to
16		Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood
17		Pressure with Lifetime Risk of Cardiovascular Disease. JAMA - J Am Med Assoc.
18		2019;322(14):1381-1391. doi:10.1001/jama.2019.14120
19	6.	Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million
20		people identifies 535 new loci associated with blood pressure traits. Nat Genet.
21		2018;50(10):1412-1425. doi:10.1038/s41588-018-0205-x
22	7.	Astle WJ, Elding H, Jiang T, et al. The Allelic Landscape of Human Blood Cell Trait
23		Variation and Links to Common Complex Disease. Cell. 2016;167(5):1415-1429.e19.
24		doi:10.1016/J.CELL.2016.10.042

1 8. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performin	g Mendelian
---	-------------

- 2 randomization investigations. *Wellcome Open Res.* 2020;4:186.
- 3 doi:10.12688/wellcomeopenres.15555.2
- 4 9. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular Risk Factors Associated with
- 5 Venous Thromboembolism. *JAMA Cardiol*. 2019;4(2):163-173.
- 6 doi:10.1001/jamacardio.2018.4537
- 7 10. Mahmoodi BK, Cushman M, Næss IA, et al. Association of traditional cardiovascular
- 8 risk factors with venous thromboembolism. *Circulation*. 2017;135(1):7-16.
- 9 doi:10.1161/CIRCULATIONAHA.116.024507
- 10 11. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian
- randomisation to assess potential benefit of clinical intervention. *Bmj*. 2012;345(nov06
  1):e7325-e7325. doi:10.1136/bmj.e7325
- 13 12. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-
- 14 Related Characteristics of UK Biobank Participants With Those of the General
- 15 Population. Am J Epidemiol. 2017;186(9):1026-1034. doi:10.1093/aje/kwx246
- 16 13. Giri A, Hellwege JN, Keaton JM, et al. Trans-ethnic association study of blood
- 17 pressure determinants in over 750,000 individuals. *Nat Genet*. 2019;51(1):51-62.
- 18 doi:10.1038/s41588-018-0303-9
- 19 14. Leadership Board BPS. *Tackling High Blood Pressure: From Evidence into Action.*;
   20 2014.
- Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence
  and control. *Circulation*. 2016;134(6):441-450.
- 23 doi:10.1161/CIRCULATIONAHA.115.018912

24

## 1 Figures

Disease	Cases		Causal estimate	p value
Coronary Artery Disease	29278	<b>⊢⊷</b> ₁	1.59 (1.45, 1.74)	p<0.001
Ischemic Cerebrovascular Disease (all)	8084		1.52 (1.39, 1.66)	p<0.001
Ischemic Stroke	4602	<b>⊢</b> =−1	1.70 (1.52, 1.90)	p<0.001
Transient Ischemic Attack	3962	<b>⊢</b> ∎−1	1.34 (1.19, 1.51)	p<0.001
Hemorrhagic Stroke (all)	1981	→	1.43 (1.21, 1.69)	p<0.001
Intracerebral Hemorrhage	1064	► <u></u>	1.32 (1.06, 1.66)	p=0.015
Subarachnoid Hemorrhage	1084	H	1.54 (1.22, 1.94)	p<0.001
Aortic Aneurysm (all)	1849		1.26 (1.02, 1.56)	p=0.032
Abdominal Aortic Aneurysm	1094	<b>⊢</b> → → →	1.20 (0.93, 1.56)	p=0.169
Thoracic Aortic Aneurysm	347		1.19 (0.79, 1.77)	p=0.405
Venous Thromboembolism (all)	14097	) <del></del>	0.90 (0.80, 1.01)	p=0.074
Deep Vein Thrombosis	9454	+	0.88 (0.77, 1.00)	p=0.044
Pulmonary Embolism	6148	<b>F</b> − <b>a</b> −1	0.91 (0.79, 1.05)	p=0.195
Peripheral Vascular Disease	3415	<b>⊢-</b> ∎-1	1.28 (1.11, 1.46)	p<0.00
Aortic Valve Stenosis	2244	F = -1	1.74 (1.48, 2.04)	p<0.00*
Atrial Fibrillation	16945	<b>⊢−</b> →	1.32 (1.21, 1.42)	p<0.001
Heart Failure	6712	<b>⊢</b> ⊷-1	1.38 (1.25, 1.53)	p<0.00*
Dilated Cardiomyopathy	720	► <b>-</b>	1.61 (1.24, 2.10)	p<0.00*
Endocarditis	691	<b>⊢ −</b> − 1	1.49 (1.12, 1.99)	p=0.007
Rheumatic Heart Disease	2817	<b>⊢ −</b> − 1	1.32 (1.13, 1.53)	p<0.001
Chronic Kidney Disease	6321	<b>⊢</b> ∎−	1.39 (1.24, 1.55)	p<0.001

2

3 Figure 1 Mendelian randomization estimates (odds ratio with 95% confidence interval per 10 mmHg increase in

4 genetically-predicted SBP) using the inverse-variance weighted method.

5

6



1





## 1 Tables

2 **Table 1** Baseline characteristics of participants in the analytic subset of the UK Biobank study

	0 "	Genetic risk score percentile		
	Overall _	Lower 50%	Upper 50%	P-value
Number of participants (n)	367,703	183,822	183,821	-
Mean (SD) age at survey / years	57.2 (8.0)	57.2 (8.0)	57.2 (8.0)	0.26
Number (%) of females	198,902 (54.1)	99,564 (54.2)	99,307 (54.0)	0.39
Mean (SD) body mass index / kg/m <sup>2</sup>	27.4 (4.8)	27.4 (4.8)	27.3 (4.7)	< 0.001
Mean (SD) low density lipoprotein / mmol/L	3.57 (0.87)	3.59 (0.87)	3.55 (0.87)	< 0.001
Number of deaths (%)	8033 (2.2)	3925 (2.1)	4105 (2.2)	0.04
Number of cardiovascular events (%)	7145 (1.9)	3291 (1.8)	3853 (2.1)	< 0.001
Number of cardiovascular events (fatal) (%)	1422 (0.4)	682 (0.4)	740 (0.4)	0.12
Number of cardiovascular events	5723 (1.6)	2609 (1.4)	3113 (1.7)	< 0.001
Number of cerebrovascular events (fatal) (%)	2714 (0.7)	1217 (0.7)	1497 (0.8)	<0.001
Number of current smokers (%)	37,866 (10.3)	19,099 (10.4)	18,763 (10.2)	0.07
Number of current alcohol drinkers (%)	342,797 (93.4)	171,486 (93.4)	171,260 (93.3)	0.25
Number of participants taking anti-	74,556 (20.4)	29,841 (16.4)	44,702 (24.5)	<0.001
Mean (SD) systolic blood pressure / mmHg	137.7 (18.6)	135.6 (18.2)	139.7 (18.8)	<0.001
Mean (SD) diastolic blood pressure / mmHg	82.0 (10.1)	81.1 (10.0)	82.8 (10.2)	< 0.001

3 Genetic risk score was calculated from 256 variants previously associated with a blood pressure trait at  $p < 5 \times 10^{-8}$ 

4 in data from the International Consortium for Blood Pressure excluding UK Biobank participants.

5